UAMS Myeloma Center, Little Rock, AR
Nishanth Thalambedu , Waqas Ullah , Sravani Gundarlapalli
Background: Pancreatic cancer (PC) has a strong association with venous thromboembolism (VTE) but the impact of it on mortality and morbidity is unknown. Inpatient costs contribute significantly to the overall cancer care costs even though there is a modest improvement in survival of pancreatic cancer patients. This study aims to determine the mortality trends and associated health care utilization in PC patients with and without VTE and to analyze its impact on hospitalized patients. Methods: We used National Inpatient Sample (NIS) to extract data for all patients above 18years of age hospitalized with a primary diagnosis of Pancreatic cancer from 2002-2018 using ICD-9 and ICD-10 codes. Unadjusted odds ratio for dichotomous outcomes were calculated, and independent t test analysis was done for continuous outcomes. Results: The odds of all-cause mortality (OR 1.35, 95% CI 1.33-1.37, p<0.001) and stroke (OR 1.82, 95% CI, 1.76-1.87, p<0.001) were significantly higher in pancreatic cancer patients with VTE compared to without VTE. PC patients with VTE were found to have significantly higher average cost of hospitalization (US $56101 vs US $46325, p<0.001) and longer length of stay(LOS) (8.20 vs 6.83, p<0.001) when compared to patients without VTE. Conclusions: Hospitalized PC patients with VTE have higher odds of mortality and stroke when compared to PC patients without VTE. Similarly, VTE in PC patients is shown to increase the hospitalization costs and overall length of stay.
Variable | No VTE | VTE | uOR (95% CI) | p=value |
---|---|---|---|---|
Mortality | 186199 (9.1%) | 20439 (11.8%) | 1.35 (1.33-1.37) | <0.0001 |
Stroke | 34628 (1.7%) | 5216 (3%) | 1.82 (1.76-1.87) | <0.0001 |
Continuous Variables | No VTE (2058088) | VTE(173028) | P-value |
---|---|---|---|
Length of stay | 6.83 ± 6.997 | 8.20 ± 8.391 | <0.0001 |
Total charges | 46325.59 ± 66711.056 | 56101.0± 85275.526 | <0.0001 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Zunairah Shah
2023 ASCO Annual Meeting
First Author: Ankushi Sanghvi
2024 ASCO Annual Meeting
First Author: Arun Kumar
2023 ASCO Annual Meeting
First Author: Alekhya Pagidipally